EA202190058A1 - Композиции фосфорамидатных производных нуклеозидных лекарственных средств - Google Patents

Композиции фосфорамидатных производных нуклеозидных лекарственных средств

Info

Publication number
EA202190058A1
EA202190058A1 EA202190058A EA202190058A EA202190058A1 EA 202190058 A1 EA202190058 A1 EA 202190058A1 EA 202190058 A EA202190058 A EA 202190058A EA 202190058 A EA202190058 A EA 202190058A EA 202190058 A1 EA202190058 A1 EA 202190058A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
nuc
relates
phosphoramidate derivatives
nucleoside drugs
Prior art date
Application number
EA202190058A
Other languages
English (en)
Inventor
Гордон Кенновин
Хью Гриффит
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA202190058A1 publication Critical patent/EA202190058A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей 5-фтор-2'-дезоксиуридин-5'-O-[1-нафтил(бензокси-L-аланинил)]фосфат (NUC-3373) и полярный апротонный растворитель, который не является диметилацетамидом (DMA). Изобретение также относится к способу лечения рака, включающему введение нуждающемуся в этом субъекту фармацевтической композиции, содержащей NUC-3373 и полярный апротонный растворитель, который не является диметилацетамидом (DMA). Настоящее изобретение также относится к наборам для лечения рака, содержит композицию, содержащую NUC-3373.
EA202190058A 2015-12-23 2016-12-21 Композиции фосфорамидатных производных нуклеозидных лекарственных средств EA202190058A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522764.8A GB201522764D0 (en) 2015-12-23 2015-12-23 Formulations of phosphate derivatives

Publications (1)

Publication Number Publication Date
EA202190058A1 true EA202190058A1 (ru) 2021-06-30

Family

ID=55311533

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891471A EA037320B1 (ru) 2015-12-23 2016-12-21 Композиция, содержащая 5-фтор-2'-дезоксируидин-5'-o-[1-нафтил (бензокси-l-аланинил] фосфат, ее применение, способ лечения рака и набор
EA202190058A EA202190058A1 (ru) 2015-12-23 2016-12-21 Композиции фосфорамидатных производных нуклеозидных лекарственных средств

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201891471A EA037320B1 (ru) 2015-12-23 2016-12-21 Композиция, содержащая 5-фтор-2'-дезоксируидин-5'-o-[1-нафтил (бензокси-l-аланинил] фосфат, ее применение, способ лечения рака и набор

Country Status (20)

Country Link
US (3) US20180369266A1 (ru)
EP (1) EP3393453A1 (ru)
JP (2) JP6913095B2 (ru)
KR (1) KR20180091919A (ru)
CN (1) CN108697636A (ru)
AU (3) AU2016375866B2 (ru)
BR (2) BR122023000551B1 (ru)
CA (1) CA3008751C (ru)
CL (1) CL2018001672A1 (ru)
EA (2) EA037320B1 (ru)
GB (1) GB201522764D0 (ru)
HK (1) HK1255108A1 (ru)
IL (1) IL260008A (ru)
MA (1) MA44117A (ru)
MX (2) MX2018007794A (ru)
MY (1) MY196741A (ru)
PH (1) PH12018501341A1 (ru)
SA (1) SA518391858B1 (ru)
SG (2) SG10202008554RA (ru)
WO (1) WO2017109491A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CN104974206B (zh) 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
AU2015352203B2 (en) 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
WO2023218202A2 (en) 2022-05-12 2023-11-16 NuCana plc Cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185301A1 (en) 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
EP1845787B1 (en) 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
PE20120013A1 (es) * 2009-01-09 2012-02-02 Univ Cardiff Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
KR101201956B1 (ko) 2009-03-18 2012-11-19 신동헌 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물
KR20110128947A (ko) 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
CN104974206B (zh) * 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
WO2013070887A1 (en) 2011-11-10 2013-05-16 Inhibitex, Inc. Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
BR112014017163A8 (pt) 2012-01-20 2017-07-04 Aratana Therapeutics Nv composição de colírio
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9737605B2 (en) * 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
MX2020004054A (es) * 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
AU2015352203B2 (en) * 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
CA3008751A1 (en) 2017-06-29
EP3393453A1 (en) 2018-10-31
MX2021010601A (es) 2021-09-28
KR20180091919A (ko) 2018-08-16
BR112018012951A2 (pt) 2018-12-11
BR122023000551B1 (pt) 2023-12-05
US20220031728A1 (en) 2022-02-03
GB201522764D0 (en) 2016-02-03
JP2021165310A (ja) 2021-10-14
AU2016375866B2 (en) 2022-06-09
WO2017109491A1 (en) 2017-06-29
BR112018012951B1 (pt) 2023-12-12
SA518391858B1 (ar) 2022-10-30
MY196741A (en) 2023-05-03
HK1255108A1 (zh) 2019-08-02
CA3008751C (en) 2023-10-03
CN108697636A (zh) 2018-10-23
JP2018538342A (ja) 2018-12-27
SG10202008554RA (en) 2020-10-29
EA201891471A1 (ru) 2018-12-28
JP6913095B2 (ja) 2021-08-04
US20180369266A1 (en) 2018-12-27
AU2022211797A1 (en) 2022-08-25
US11786544B2 (en) 2023-10-17
AU2022211797B2 (en) 2024-04-04
CL2018001672A1 (es) 2019-02-01
SG11201805318SA (en) 2018-07-30
AU2016375866A1 (en) 2018-07-05
US20240082287A1 (en) 2024-03-14
AU2024203637A1 (en) 2024-06-20
EA037320B1 (ru) 2021-03-11
IL260008A (en) 2018-07-31
PH12018501341A1 (en) 2019-02-18
MX2018007794A (es) 2019-07-01
MA44117A (fr) 2021-03-31

Similar Documents

Publication Publication Date Title
EA202190058A1 (ru) Композиции фосфорамидатных производных нуклеозидных лекарственных средств
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
EA201892745A1 (ru) Фосфорамидатные производные нуклеозида в качестве противораковых агентов
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
EA201792169A1 (ru) 5'-замещенные нуклеозидные соединения
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MD4584C1 (ru) (2R,5S,13aR)-7,9-диоксо-10-((2,4,6-трифторбензил)карбамоил)-2,3,4,5,7,9,13,13a-октагидро-2,5-метанопиридо[1ʹ,2ʹ:4,5]пиразино[2,1-b][1,3]оксазепин-8-олят натрия
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
GEP20237502B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EA201892769A3 (ru) Сложные диэфиры ациклических нуклеозидфосфонатов
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
EA202091341A1 (ru) Пиразолопиримидины, обладающие активностью в отношении респираторно-синцитиального вируса (rsv)
EA201990780A1 (ru) Твердая форма соединения 4'-тио-2'-фторнуклеозид фосфамида и способ его получения и применения
MX2021006992A (es) Análogos de nucleósidos de ciclobutilo como antivirales.